Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

SNSS 7.14 -0.34 (-4.55%)
price chart
Sunesis Pharmaceuticals, Inc. (SNSS): Ken Griffin's Citadel Boosts His Stake
Citadel Advisors, a fund managed by Ken Griffin, has disclosed boosting its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Traders Buy High Volume of Call Options on Sunesis Pharmaceuticals (SNSS)  Mideast Time
Related articles »  
Stocks Under Consideration - Amkor Technology, Inc. (NASDAQ:AMKR ...
Amkor Technology, Inc. (NASDAQ:AMKR) is pleased to announce that it has received the 2013 Excellent Service Provider Award from Semiconductor Manufacturing International Corporation (SMIC), the third consecutive year Amkor has earned this award.
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences ...
Sunesis Pharmaceuticals Inc.'s stock surged 3.94%, to close Monday's session at $7.38, after oscillating between $7.11 and $7.47.
Related articles »  
Active Movers - Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Alpha Pro Tech ...
New York, NY- 25 Sep, 2014 - (Techsonian) �OTC PENNY ALERTS has a finger on the pulse of many sectors including renewable energy, oil, pharmaceuticals, mining, finance, technology and healthcare. Whenever a breakout micro-cap or small-cap ...
Related articles »  
High-beta stocks produce higher returns: Sunesis Pharmaceuticals, Inc. (SNSS ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has beta value of 2.48. The company has the market capitalization of $447.26 billion.
Stocks to Keep Your Eyes On: Sunesis Pharmaceuticals, Inc. (SNSS), Aspen ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) plummeted 3.73 percent to $7.49 in the last trading session after Wedbush cut its ratings for the biopharmaceutical company from �Outperform� to �Neutral� in a research report sent to investors on August 29.
Notable Downgrades: Splunk Inc (SPLK), Mobile TeleSystems (MBT), Sunesis ...
Analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS) to 'Neutral' from 'Outperform'.
Related articles »  
Sunesis Pharmaceuticals Stock Rating Lowered by Wedbush (SNSS)
Sunesis Pharmaceuticals, Inc. logo Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by investment analysts at Wedbush from an �outperform� rating to a �neutral� rating in a note issued to investors on Friday, TheFlyOnTheWall.
Insider Selling: Sunesis Pharmaceuticals major shareholder Sells 300700 ...  Watch List News (press release)
Sunesis Pharmaceuticals CFO Sells $80000 in Stock (SNSS)  sleekmoney
Related articles »  
Morning Watch List : Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Move, Inc ...
On 29 Aug Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an �outperform� rating to a �neutral� rating in a research note on Friday.
Sunesis Pharmaceuticals major shareholder Sells $2125599 in Stock (SNSS)
Sunesis Pharmaceuticals logo Sunesis Pharmaceuticals (NASDAQ:SNSS) major shareholder Forest Baskett sold 266,700 shares of the company's stock on the open market in a transaction that occurred on Friday, August 29th. The stock was sold at an ...
Sunesis Pharmaceuticals CFO Eric Bjerkholt Unloads 10000 Shares (SNSS)  Watch List News (press release)
Related articles »